97 related articles for article (PubMed ID: 16170195)
41. Trastuzumab-associated peripheral vascular toxicity.
Pansegrau GK; Grant DR; Norris B; Gelmon KA
J Clin Oncol; 2007 Apr; 25(11):1438-40. PubMed ID: 17416865
[No Abstract] [Full Text] [Related]
42. [Metastatic breast cancer].
Krankenpfl J; 2003; 41(1-3):38. PubMed ID: 12718266
[No Abstract] [Full Text] [Related]
43. Translation, please.
Bleiweiss IJ; Raptis G
Lancet Oncol; 2007 Dec; 8(12):1044-1045. PubMed ID: 18054869
[No Abstract] [Full Text] [Related]
44. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
Bertheau P; Plassa F; Espié M; Turpin E; de Roquancourt A; Marty M; Lerebours F; Beuzard Y; Janin A; de Thé H
Lancet; 2002 Sep; 360(9336):852-4. PubMed ID: 12243922
[TBL] [Abstract][Full Text] [Related]
45. Paclitaxel plus bevacizumab for metastatic breast cancer.
Haines IE; Miklos GL
N Engl J Med; 2008 Apr; 358(15):1637; author reply 1637-8. PubMed ID: 18403775
[No Abstract] [Full Text] [Related]
46. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.
Fuller CK; Charlson JA; Dankle SK; Russell TJ
J Am Acad Dermatol; 2010 Oct; 63(4):e83-4. PubMed ID: 20846560
[No Abstract] [Full Text] [Related]
47. Optimizing dose-dense regimens for early-stage breast cancer.
Morris PG; Hudis CA
Nat Rev Clin Oncol; 2010 Dec; 7(12):678-9. PubMed ID: 21116238
[No Abstract] [Full Text] [Related]
48. Race to report: are vascular endothelial growth factor genetic polymorphisms associated with outcome in advanced breast cancer patients treated with Paclitaxel plus bevacizumab?
Tan MH; Tan CS; Lim WY
J Clin Oncol; 2009 Mar; 27(8):1342; author reply 1342-3. PubMed ID: 19188671
[No Abstract] [Full Text] [Related]
49. Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream.
Di Leo A; Moretti E
J Clin Oncol; 2008 Nov; 26(31):5011-3. PubMed ID: 18768431
[No Abstract] [Full Text] [Related]
50. High-dose chemotherapy for breast cancer: we have not heard the final word.
Bearman SI
Cancer Invest; 2000; 18(5):494-7. PubMed ID: 10834035
[No Abstract] [Full Text] [Related]
51. [Therapy concept: herceptin in combination with arimidex].
von Minckwitz G
Onkologie; 2002 Dec; 25 Suppl 5():22 ; discussion 22-4. PubMed ID: 23573617
[No Abstract] [Full Text] [Related]
52. Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.
Hirte HW; Hotte SJ
J Clin Oncol; 2008 Jul; 26(20):3301-2. PubMed ID: 18490647
[No Abstract] [Full Text] [Related]
53. [Therapy of metastatic breast cancer at the Ulm Tumor Center in 1980 and 1990].
Porzsolt F
Onkologie; 1990 Dec; 13(6):468-72. PubMed ID: 2092286
[No Abstract] [Full Text] [Related]
54. Bilateral phrenic nerve paralysis as a manifestation of paraneoplastic syndrome.
Otrock ZK; Barada WM; Sawaya RA; Saab JF; Bazarbachi AA
Acta Oncol; 2010; 49(2):264-5. PubMed ID: 19929565
[No Abstract] [Full Text] [Related]
55. Avastin withdrawal symptoms.
Lynce F; Swain SM
Expert Opin Pharmacother; 2012 Feb; 13(3):293-8. PubMed ID: 22263961
[No Abstract] [Full Text] [Related]
56. Stimulation of human breast cancer in vivo. Experimental findings and clinical results.
Baldini E; Gardin G; Naso C; Pronzato P; Rosso R; Rubagotti A; Monzeglio C; Brema F; Pastorino G; Amadori D
Ann N Y Acad Sci; 1993 Nov; 698():418-22. PubMed ID: 8279781
[No Abstract] [Full Text] [Related]
57. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
Hietanen P; Blomqvist C; Wasenius VM; Niskanen E; Franssila K; Nordling S
Br J Cancer; 1995 May; 71(5):1029-32. PubMed ID: 7734295
[TBL] [Abstract][Full Text] [Related]
58. Synchronous bilateral breast cancer in a patient with kindler syndrome.
Tonyali O; Tufan G; Benekli M; Coskun U; Buyukberber S
Clin Breast Cancer; 2012 Apr; 12(2):145-6. PubMed ID: 22054710
[No Abstract] [Full Text] [Related]
59. [Future direction of adjuvant chemotherapy for breast cancer following new risk categories of St. Gallen Consensus].
Osaki A; Saeki T
Nihon Rinsho; 2007 Jun; 65 Suppl 6():407-13. PubMed ID: 17682185
[No Abstract] [Full Text] [Related]
60. Study supports activity of gemcitabine in treatment of early-stage breast cancer.
Oncology (Williston Park); 2007 Oct; 21(11):1285. PubMed ID: 18080615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
